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Abstract  
Background:  
Therapy of relapsing-remitting multiple sclerosis with Natalizumab (Tysabri, Biogen Idec) has 
been shown to be effective in the reduction of the clinical relapse rate and disability 
progression. However, real-life, longitudinal data, including years before baseline, are rare. 
Methods: 
An observational, single-center study was carried out. We analyzed data from 64 
consecutive MS patients.  
Results: 
After one year of treatment (n=64), EDSS decreased by 0.47 points (p=0.047), the 
annualized relapse rate (ARR) by 82% (p<0.001). After two years (n=41), EDSS was still 
reduced by 0.28 (n.s.) and ARR by 69% (p<0.001). After three years (n=23), EDSS was 
reduced by 0.26 (n.s.), ARR by 77% (p<0.001). EDSS and ARR reduction did not depend on 
baseline ARR (1-2 vs. >2) or EDSS and were not biased by exceptional high disease activity 
or relapses around baseline. 
Conclusion:  
These real life data reinforce that natalizumab is effective over years, reduces ARR and 
stabilizes EDSS independent of baseline ARR, baseline EDSS or baseline treatment.   
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Introduction 
In the pivotal trial of natalizumab therapy of relapsing-remitting multiple sclerosis (RRMS; 
AFFIRM) [1], the clinical relapse rate was reduced by 68% compared with placebo in the first 
year of treatment. Furthermore, the probability of disability progression was decreased [1]. 
Several subsequent studies have confirmed the efficacy of natalizumab [2-9]. However, real-
life longitudinal data, including years before baseline and especially on patients with a high 
EDSS at baseline, are rare. The present study provides such real-life data on 64 
natalizumab-treated MS patients with a mean baseline EDSS of 4.5±1.7.     
 
Patients and Methods 
We conducted our study in compliance with the principles of the Declaration of Helsinki.  
 
An observational, monocenter study was carried out. Inclusion criteria were natalizumab 
treatment of RRMS according to the modified McDonald criteria [10] and availability of 
standardized clinical data, collected in our MS center, on at least one year before and one 
year after initiation of natalizumab treatment. Relapses were defined according to McDonald 
criteria. PASW statistics version 18 was used for ANOVA statistics (IBM,NY). When data 
were only available for a subset of patients, e.g. the 2y and 3y follow-up data, we compared 
the available data with those patients’ baseline data only and excluded baseline data of the 
other patients. Data were exploratively stratified by baseline EDSS, baseline ARR, median 
disease duration and prior therapies.  
  
Results 
Sixty-four consecutive patients were enrolled. Two additional patients developed persisting 
anti-natalizumab-antibodies, one developed an allergic reaction and one developed a 
progressive multifocal leukoencephalopathy (PML). These four patients were not included 
into further analyses. At baseline, mean age ±1 standard deviation was 41±10 yr. (range: 22-
68). Forty-seven patients (0.73) were female, 17 (0.27) were male. Disease duration was 
9.9±7.5 yr. (range: 0-29). Sixteen (0.25) patients had no prior immunomodulating or 
Natalizumab: 3y real-life data 
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immunosuppressive therapy other than steroids, 33 (52%) had been treated with beta-
interferons only, 2 (3%) with glatiramer acetate only, 6 (9%) with both beta-interferons and 
glatiramer acetate one after another, and 7 (11%) had immunosuppressant treatment after 
beta-interferon and/ or glatiramer acetate treatment. Two patients had had an additional 
treatment with immunoglobulins.  
 
Initiation of natalizumab treatment reduced the ARR in the entire population as well as in 
subgroups defined by a moderate or high ARR at baseline, respectively (Table 1, Figure 1a). 
The ARR was significantly reduced over the three years observed. In addition, natalizumab 
treatment also reduced the EDSS in the first year (Table 1). EDSS after two and three years 
was still lower in comparison to the baseline EDSS of the respective patients, but this was 
not significant, consistent with the smaller effect size and the smaller sample group. EDSS 
reduction was similar when stratified by limitation versus non-limitation of walking distance 
(Figure 1b). ARR and EDSS reduction were also independent of age, gender, or disease 
duration (not shown). Concerning patients without previous treatment, ARR baseline versus 
first year was 2.52±0.87 versus 0.38±0.74 (=85% reduction; p<0.001). For patients receiving 
therapy with interferons or glatiramer acetate before the time of natalizumab initiation, ARR 
baseline versus first year was 1.95±1.0 versus 0.29±0.46 (=85% reduction; p<0.001). In the 
first year of natalizumab treatment, EDSS improved in 22/64 (0.34) of patients and was 
stable in further 31/64 (0.48) patients. After two years, EDSS was better than baseline in 
12/37 (0.32) and equal in 18/37 (0.49), and, after three years, EDSS was better in 6/23 (0.26) 
and equal in 13/23 (0.57). Clinical freedom of disease activity, i.e. no relapses and improved 
or stable EDSS, was observed in 43/59 (0.73), 13/37 (0.35), and 8/23 (0.35) patients after 
one, two and three years of natalizumab treatment. Regarding the years before baseline, 
ARR in the first year of treatment was significantly lower in comparison to one (p=0.012) and 
two (p=0.001) years before baseline, and also ARR of the second and third year after 
initiation was lower compared with one (p=0.017 and p=0.010) and two years (p=0.042 and 
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p=0.022) before treatment initiation (Table 1, Figure 1a). This was not significant for EDSS 
(Table 1).  
Discussion 
Natalizumab has been shown to be effective in the treatment of RRMS [1-9]. However, 
longitudinal real-life data are rare. The Swedish national post-marketing surveillance study 
demonstrated sustained efficacy of natalizumab treatment for the Swedish population [9]. For 
the present population, similar results were obtained with data collected in our MS-center 
standardized to the McDonald criteria [10].  
 
Natalizumab treatment is often initiated after a period of active disease resulting in a high 
baseline ARR. It cannot be excluded that, in the natural course of disease, the ARR of the 
next year would have been lower again, even without initiation of natalizumab therapy. 
Natural regression to the mean disease activity might be an important bias in respective 
studies using baseline data for the analysis of natalizumab efficacy, as Natalizumab often is 
initiated in a periods of high disease activity. Thus, comparison of follow-up data during 
Natalizumab therapy should not only been performed with baseline, but also with the disease 
activity before baseline. In our study, the ARR in the first three years was significantly lower 
not only in comparison to baseline data, but also to one and two years before baseline, 
demonstrating a sustained efficacy not derived from a bias concerning the evaluation of 
baseline data. Moreover, ARR reduction in the first year was identical in patients without 
treatment and patients under treatment with interferons or glatiramer acetate at treatment 
initiation. These data confirm the efficacy of natalizumab in patients with active disease, 
regardless if treatment naïve/ currently untreated or under first-line immunomodulating 
therapy. In our group of patients, the efficacy of natalizumab over three years according to 
the reduction on ARR and, in part, EDSS, was confirmed. The effect of natalizumab on 
patients with more advanced disease severity, i.e. with a reduced walking distance, was 
comparable to patients without reduced walking distance showing a remarkable stabilization 
Kommentar [ML3]: immer gross oder 
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and slight improvement on EDSS indicating the positive effect of Tysabri on EDSS compared 
to the natural course of the disease. [11] 
 
 
 
Conclusion 
In conclusion, our study reinforces that natalizumab is efficient in the treatment of RRMS 
independent of baseline ARR, baseline EDSS or baseline treatment. Improvement after 
baseline is not likely to be biased by exceptionally high disease activity at the time-point of 
Tysabri initiation as shown by the data from year(s) before baseline. Efficacy of natalizumab 
therapy persists over years. The benefits of natalizumab treatment must be weighed against 
the risks.  
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Figure title and legend: 
 
Figure 1a: Annualized replapse rate  
Annualized relapse rate (ARR) before and after initiation of natalizumab treatment. * p<0.05, 
***p<0.001  
Figure 1b: EDSS   
EDSS differences from baseline (t=0: EDSS=4.52) beginning two years before to three years 
after therapy. * p<0.05, **p<0.01 
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